Evidence map›Paper›PMID 35671062›Full record

ArticleBlood advances2022

Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.

Daniel C Ferguson, J Robert McCorkle, Kelly R Barnett, Erik J Bonten, Brennan P Bergeron, Kashi Raj Bhattarai, Wenjian Yang, Colton Smith, Baranda S Hansen, Richa Bajpai and 16 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 1 country.

Daniel C FergusonHematological Malignancies Program and Center for Precision Medicine in Leukemia.
J Robert McCorkleHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0002-5028-8853
Kelly R BarnettHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Erik J BontenHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Brennan P BergeronHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0003-4292-2903
Kashi Raj BhattaraiHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Wenjian YangHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0002-7305-5649
Colton SmithHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Baranda S HansenDepartment of Cell and Molecular Biology and Center for Advanced Genome Engineering, and.
Richa BajpaiDepartment of Cell and Molecular Biology and Center for Advanced Genome Engineering, and.
Qian DongHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Robert J AutryHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Yoshihiro GochoHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Jonathan D DiedrichHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Kristine R CrewsHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0002-7558-558X
Shondra M Pruett-MillerDepartment of Cell and Molecular Biology and Center for Advanced Genome Engineering, and.ORCID 0000-0002-3793-585X
Kathryn G RobertsHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0001-7626-4043
Wendy StockHematopoiesis and Hematological Malignancies Program, University of Chicago, Chicago, IL; and.
Charles G MullighanHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0002-1871-1850
Hiroto InabaHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Sima JehaHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Ching-Hon PuiHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0003-0303-5658
Jun J YangHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Mary V RellingHematological Malignancies Program and Center for Precision Medicine in Leukemia.ORCID 0000-0002-3720-9591
William E EvansHematological Malignancies Program and Center for Precision Medicine in Leukemia.
Daniel SavicHematological Malignancies Program and Center for Precision Medicine in Leukemia.
St. Jude Children's Research Hospital · USUniversity of Chicago · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Pharmacogenomics of Childhood Leukemia ALLR01CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1985 to 2019
$3.6M
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcomeR01CA234490 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SAVIC, DANIEL · 2019 to 2023
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA036401NCI NIH HHS R01 CA234490NIGMS NIH HHS P50 GM115279NIGMS NIH HHS U01 GM092666
6 · The paper itself

Abstract

Understanding the genomic and epigenetic mechanisms of drug resistance in pediatric acute lymphoblastic leukemia (ALL) is critical for further improvements in treatment outcomes. The role of transcriptomic response in conferring resistance to l-asparaginase (LASP) is poorly understood beyond asparagine synthetase (ASNS). We defined reproducible LASP response genes in LASP-resistant and LASP-sensitive ALL cell lines as well as primary leukemia samples from newly diagnosed patients. Defining target genes of the amino acid stress response-related transcription factor activating transcription factor 4 (ATF4) in ALL cell lines using chromatin immunoprecipitation sequencing (ChIP-seq) revealed 45% of genes that changed expression after LASP treatment were direct targets of the ATF4 transcription factor, and 34% of these genes harbored LASP-responsive ATF4 promoter binding events. SLC7A11 was found to be a response gene in cell lines and patient samples as well as a direct target of ATF4. SLC7A11 was also one of only 2.4% of LASP response genes with basal level gene expression that also correlated with LASP ex vivo resistance in primary leukemia cells. Experiments using chemical inhibition of SLC7A11 with sulfasalazine, gene overexpression, and partial gene knockout recapitulated LASP resistance or sensitivity in ALL cell lines. These findings show the importance of assessing changes in gene expression following treatment with an antileukemic agent for its association with drug resistance and highlight that many response genes may not differ in their basal expression in drug-resistant leukemia cells.

Indexed as

Aspartate-Ammonia LigasePrecursor Cell Lymphoblastic Leukemia-LymphomaActivating Transcription Factor 4Amino AcidsAsparaginaseCell Line, TumorChildHumansActivating Transcription Factor 4Amino AcidsAsparaginaseAspartate-Ammonia Ligase

Identifiers

PMID35671062
PMCPMC9198938
OpenAlexW4281744365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.